After deeming success unlikely, Merck KGaA cuts lung cancer trial to consider future of ATR inhibitor

Merck KGaA's North American healthcare business, EMD Serono, is discontinuing a clinical trial for a med once considered a star in its oncology program, but an interim analysis has the company changing tactics.